ALPHARETTA, Ga., July 16, 2015 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (OTCQB:SNWV), a leading shock wave technology company, announced today the results of two poster presentations and a laboratory demonstration at the Center for Biofilm Engineering's 2015 Biofilm Science and Technology Meeting held at Montana State University in Bozeman, Montana on July 13-16, 2015. A video of the biofilm removal using SANUWAVE's shock wave technology can be viewed on the Company's website at www.sanuwave.com.
SANUWAVE's patented shock wave technology was evaluated in-vitro for effects on difficult to remove biofilms created by both Gram-negative bacteria (Pseudomonas aeruginosa) and Gram-positive bacteria (Staphylococcus aureus). Biofilms were exposed to focused acoustic shock waves and the application was performed without any contact between the shock wave applicator and the biofilm. The shock wave application to the biofilms resulted in a greater than three (3) log reductions (99.9%) from the surfaces exposed to the shock waves in certain tests for both bacteria test species. These results indicate that SANUWAVE's technology can effectively remove biofilms from surfaces using only the mechanical stresses produced by the shock waves. These tests indicate that SANUWAVE's technology could potentially reduce or eliminate the need to use chemicals, enzymes, or antibiotics to destroy and remove biofilms.
"We are confident that our patented technology's results on biofilm removal will enable us to accelerate our discussions with potential strategic partners for us to continue exploring practical applications for our shock wave technology in biofilm elimination for both industrial and medical applications," said Kevin A. Richardson II, Chairman of the board of directors of SANUWAVE.
SANUWAVE Health Inc., and its wholly owned subsidiary SANUWAVE, Inc., now have 40 patents (issued or pending) in the field of shock wave technology used in medical and non-medical applications.
About the Center for Biofilm Engineering
Montana State University's Center for Biofilm Engineering has been a world leader in biofilm research for more than 20 years. A prestigious 11-year National Science Foundation Engineering Research Center grant awarded in 1990 paved the way for the CBE's influence in the emerging field of biofilm research. The Center's three-fold emphasis in research, education, and industry continues to produce results and exciting opportunities for students, staff, and faculty—as well as industrial partners.
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (OTCQB:SNWV) (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE's portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body's normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, Australia and New Zealand. In the U.S., dermaPACE is currently under the FDA's Premarket Approval (PMA) review process for the treatment of diabetic foot ulcers. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE's shock wave technology for non-medical uses, including energy, water, food and industrial markets.
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company's product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company's ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
For additional information about the Company, visit www.sanuwave.com.